Search

Displaying results 2101 - 2110 of 8468 in total
  1. Drug

    Dobutamine

    go.drugbank.com/drugs/DB00841
    ApprovedInvestigational

    A beta-1 agonist catecholamine that has cardiac stimulant action without evoking vasoconstriction or tachycardia. It is proposed as a cardiotonic after myocardial infarction or open heart surgery.

  2. Drug

    Peginterferon alfa-2a

    go.drugbank.com/drugs/DB00008
    ApprovedInvestigational

    The use of Peginterferon alfa-2a has largely declined since newer interferon-free antiviral therapies have been developed. … Peginterferon alfa-2a is available as a fixed dose injector (tradename Pegasys) used for the treatment of chronic Hepatitis C.

  3. Drug

    Pegloticase

    go.drugbank.com/drugs/DB09208
    ApprovedInvestigational

    [L42425] Pegloticase has a similar activity to rasburicase, an enzyme that metabolizes uric acid to allantoin. … [L42425] Pegloticase has a longer terminal elimination half-life thanks to the addition of a polyethylene glycol (PEG) group.

  4. Drug

    Etomidate

    go.drugbank.com/drugs/DB00292
    ApprovedInvestigational

    It has been proposed as an induction anesthetic.

  5. Drug

    Thiothixene

    go.drugbank.com/drugs/DB01623
    Approved

    A thioxanthine used as an antipsychotic agent. Its effects are similar to the phenothiazine antipsychotics.

  6. Drug

    Copper oxodotreotide Cu-64

    go.drugbank.com/drugs/DB15873
    Approved

    [A220348] In a head-to-head trial, the former tracer detected twice as many lesions as the latter.[A220348] … [A220348] Copper Cu 64 dotatate has a longer half-life and can be produced once a day as opposed to several times a day, and lower positron energy lending to improved spatial resolution.

  7. Drug

    Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine

    go.drugbank.com/drugs/DB10061
    ApprovedInvestigational

    [L43518] Meningococcal (Groups A, C, Y, and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine, marketed as MENVEO, was first approved by the FDA in 2010.[L43518] … used to prevent invasive meningococcal disease, which is caused by bacteria _Neisseria meningitidis_ entering the bloodstream and invading the blood-brain barrier to cause a variety of infections such as

  8. Drug

    Strontium chloride

    go.drugbank.com/drugs/DB13987
    ApprovedWithdrawn

    This kind of barrier protection for tooth hypersensitivity has, however, been superseded by other toothpaste formulations and ingredients designed to be nerve calming agents instead [A33167, A33168].

  9. Drug

    Clobetasone

    go.drugbank.com/drugs/DB13158
    Approved

    Clobetasone is a corticosteroid that is often employed topically as a treatment for a variety of conditions such as eczema, psoriasis, various forms of dermatitis, and also for certain ophthalmologic conditions … Topical clobetasone butyrate has shown minimal suppression of the Hypothalamic-pituitary-adrenal axis.

  10. Drug

    Thalidomide

    go.drugbank.com/drugs/DB01041
    ApprovedInvestigationalWithdrawn

    A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. … It has been reintroduced and used for a number of inflammatory disorders and cancers.